ES2128417T3 - Formulacion y utilizacion de carotenoides en el tratamiento del cancer. - Google Patents

Formulacion y utilizacion de carotenoides en el tratamiento del cancer.

Info

Publication number
ES2128417T3
ES2128417T3 ES93903070T ES93903070T ES2128417T3 ES 2128417 T3 ES2128417 T3 ES 2128417T3 ES 93903070 T ES93903070 T ES 93903070T ES 93903070 T ES93903070 T ES 93903070T ES 2128417 T3 ES2128417 T3 ES 2128417T3
Authority
ES
Spain
Prior art keywords
lipid
carotenoid
formulation
carotenoids
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93903070T
Other languages
English (en)
Inventor
Kapil Mehta
Roman Perez-Soler
Gabriel Lopez-Berestein
Robert P Lenk
Alan C Hayman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aronex Pharmaceuticals Inc
University of Texas System
Original Assignee
Aronex Pharmaceuticals Inc
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aronex Pharmaceuticals Inc, University of Texas System filed Critical Aronex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2128417T3 publication Critical patent/ES2128417T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UNA FORMULACION DE TOXICIDAD REDUCIDA DE CAROTENOIDES QUE ES ESTABLE EN UN MEDIOAMBIENTE ACUOSO. LA FORMULACION COMPRENDE UN CAROTENOIDE, PARTICULAS PORTADORAS DE LIPIDOS (TAL COMO LIPOSOMAS), Y UN AGENTE PROMOTOR DE INTERCALACION (TAL COMO UN TRIGLICERIDO), QUE HACE QUE EL CAROTENOIDE SE DISTRIBUYA SUSTANCIALMENTE DE FORMA UNIFORME CON EL LIPIDO EN LAS PARTICULAS PORTADORAS DE LIPIDOS. LA RELACION MOLAR DE CAROTENOIDE A LIPIDO ES MAYOR QUE APROXIMADAMENTE 1:10. TAMBIEN SE PRESENTA UN METODO DE INHIBICION DEL CRECIMIENTO DE CELULAS CANCEROSAS, QUE CONSISTE EN LA ADMINISTRACION A UN SUJETO VIVO UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UNA COMPOSICION ARRIBA DESCRITA.
ES93903070T 1992-01-16 1993-01-13 Formulacion y utilizacion de carotenoides en el tratamiento del cancer. Expired - Lifetime ES2128417T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82205592A 1992-01-16 1992-01-16

Publications (1)

Publication Number Publication Date
ES2128417T3 true ES2128417T3 (es) 1999-05-16

Family

ID=25235000

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93903070T Expired - Lifetime ES2128417T3 (es) 1992-01-16 1993-01-13 Formulacion y utilizacion de carotenoides en el tratamiento del cancer.

Country Status (8)

Country Link
EP (1) EP0621773B1 (es)
JP (2) JP3691054B2 (es)
AT (1) ATE173615T1 (es)
AU (1) AU3442093A (es)
CA (1) CA2128103C (es)
DE (1) DE69322252T2 (es)
ES (1) ES2128417T3 (es)
WO (1) WO1993013751A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
DK0689426T3 (da) * 1993-03-22 2000-10-30 Cognis Australia Pty Ltd Terapeutisk middel til behandling af melanomer
JPH08510995A (ja) * 1993-03-22 1996-11-19 ベータティーン・リミテッド 水分散性治療用化合物
WO1997006790A1 (en) * 1995-08-14 1997-02-27 Oxigene, Inc. Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
WO2001074384A1 (en) * 2000-03-31 2001-10-11 Aronex Pharmaceuticals, Inc. Combined interferon alfa and liposomal-encapsulated all-trans retinoic acid, including preparation and use
WO2002032413A2 (en) * 2000-10-17 2002-04-25 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
CA2656910C (en) * 2006-07-07 2012-08-28 Tiltan Pharma Ltd. Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent
CN107753473A (zh) * 2016-08-18 2018-03-06 杭州高田生物医药有限公司 一种全反式维甲酸注射剂与应用
WO2024174011A1 (pt) * 2023-02-24 2024-08-29 Rossi Bergmann Bartira Lipossoma, método de preparo de um lipossoma, composição intranasal compreendendo lipossoma, método de preparo de composição intranasal, kit e uso da composição

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
WO1989006977A1 (en) * 1988-02-04 1989-08-10 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
IL90561A (en) * 1988-06-08 1993-08-18 Fountain Pharm Inc Method for making solvent dilution microcarriers
DE4005711C1 (es) * 1990-02-23 1991-06-13 A. Nattermann & Cie Gmbh, 5000 Koeln, De

Also Published As

Publication number Publication date
CA2128103C (en) 2004-12-28
EP0621773B1 (en) 1998-11-25
AU3442093A (en) 1993-08-03
JP2005232182A (ja) 2005-09-02
DE69322252D1 (de) 1999-01-07
ATE173615T1 (de) 1998-12-15
CA2128103A1 (en) 1993-07-22
WO1993013751A1 (en) 1993-07-22
JP3691054B2 (ja) 2005-08-31
JPH07503014A (ja) 1995-03-30
DE69322252T2 (de) 1999-08-12
EP0621773A1 (en) 1994-11-02

Similar Documents

Publication Publication Date Title
ES2104056T3 (es) Composiciones estables de porfimero sodico y metodos para su preparacion.
WO1996028148A3 (en) Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
MY110734A (en) Improvements in or relating to dioic acids.
DE3267039D1 (en) Stable s-adenosylmethionine salts, the process for their preparation and therapeutic compositions which contain them as active principle
HU883981D0 (en) Process for the production of medical preparations with antiviral or antibacterial effect
MX9206577A (es) COMPOSICIóN FARMACEUTICA PARA INHIBIR EL CRECIMIENTO DE CELULAS TUMORALES
EP0336901A3 (en) Anesthetic skin moisturizing composition and method of preparing same
HU900284D0 (en) Fungicide compositions containing acrylic acid derivatives and process for producing the active substance
GR3030528T3 (en) Viscoelastic compositions of fluorinated organic compounds
AU7593991A (en) Cosmetic composition
ES2128417T3 (es) Formulacion y utilizacion de carotenoides en el tratamiento del cancer.
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
GR3023038T3 (en) Use of coconut precursor fatty acid as insect-repellent.
ES2110572T3 (es) Composicion cosmetica que contiene un lipido y un acido hidroxi o cetocarboxilico.
SG46307A1 (en) New pyrazine derivatives the preparation and use thereof
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
WO1987000432A3 (en) Use of melatonin or related compounds for the treatment of psoriasis
CA2067365A1 (en) Illudin analogs as anti-tumor agents
SE8204873L (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
AU669946B2 (en) Lanolin/lanolin acid ester skin treatment composition
JPS5714517A (en) Whitening cosmetic
SE8800990L (sv) Hudregenererande kosmetisk komposition samt foerfarande foer framstaellning av densamma
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
JPS5626842A (en) Aliphatic acid ester of beta-thujaplicin and fair-skinning cosmetic having said ester as active component
NO912890L (no) Preparat inneholdende salicylsyre for behandling av hudsykdommer med avskalling.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 621773

Country of ref document: ES